CSL Seqirus, a Proud Champion of Pandemic Preparedness, Announces U.S. Government Award in Response to Avian Influenza

Group 1: Company Overview - CSL Seqirus has been awarded a contract by the Biomedical Advanced Research and Development Authority (BARDA) to complete the fill and finish process for a pre-pandemic vaccine as part of the National Pre-Pandemic Influenza Vaccine Stockpile (NPIVS) program [2][3] - The company will deliver approximately 4.8 million doses of a pre-pandemic vaccine that is well-matched to the currently circulating H5N1 strain [3] - CSL Seqirus operates the largest cell-based influenza vaccine production facility in the world, located in Holly Springs, NC, capable of producing up to 150 million doses within six months of a pandemic declaration [4] Group 2: Industry Context - The recent outbreaks of highly pathogenic avian influenza (HPAI) in the U.S. have prompted increased preparedness efforts, with the CDC maintaining a low risk to public health while closely monitoring the situation [3][4] - Pre-pandemic vaccines are crucial for mitigating the risk of outbreaks and providing a first line of defense before a pandemic vaccine is declared [6] - The rise in avian influenza cases, particularly HPAI A(H5N1), highlights the ongoing need for effective pandemic preparedness strategies [7]